Airway hillocks are specialized stratified squamous epithelial structures in the respiratory tract. They feature luminal barrier cells that form the apical protective layer and are maintained by a dedicated basal stem cell population. These physiologic structures represent an epithelial barrier program with distinct cellular organization and differentiation markers.
In the issue of Cancer Research discussed here, Izzo and colleagues report the existence of a distinct tumor cell population in lung squamous cell carcinoma (SCC) that mirrors the physiologic hillock program. These tumor cells are characterized by expression of KRT13 and a slow-cycling phenotype, and are described as hillock-like due to their resemblance to normal airway hillock cells. The hillock-like cell state was observed across multiple SCC models, indicating conservation of this tumor cell program in different experimental and disease contexts.
The work highlighted by this comment identifies the Kruppel-like transcription factor KLF4 as a mechanistic driver of KRT13 expression in the hillock-like tumor cells. KLF4 activity in these cells promotes the hillock-like transcriptional state, linking a defined transcription factor to the emergence of this differentiated, barrier-associated tumor cell phenotype. The association between KLF4 and KRT13 provides a molecular axis that connects an epithelial differentiation program to tumor cell identity within lung SCC.
Importantly, the KLF4-driven KRT13+ hillock-like state correlates with enrichment of potential therapeutic targets and with resistance to platinum-based chemotherapy. The authors of the original study report that this tumor cell state is associated with features that may reduce sensitivity to platinum agents commonly used in SCC treatment. By establishing this link, the study connects a physiologic epithelial barrier program to clinically relevant treatment responses and suggests that hillock-like tumor cells could underlie a mechanism of intrinsic or acquired chemoresistance in lung SCC.
The Cancer Research comment situates the Izzo et al. findings within a broader literature on KLF4 and squamous cell carcinomas. Prior studies have explored roles for KLF4 in various SCC contexts, including impacts on differentiation, tumor progression, and therapy response. The comment references the primary Izzo et al. research article (Cancer Res. 2026;86:4472–4496) as the direct source of the experimental observations and notes that the hillock-like KRT13+ program was conserved in multiple SCC models used by the investigators.
By linking the physiologic epithelial barrier—specifically the hillock cellular program—to a tumor cell state that confers treatment resistance, the study uncovers a previously uncharacterized mechanism in SCC biology. The identification of a KLF4 → KRT13 axis that defines slow-cycling, hillock-like tumor cells highlights a potential route to new therapeutic strategies: either targeting components of this axis or exploiting vulnerabilities of the enriched therapeutic targets associated with the hillock-like state. The comment underscores that these findings expand understanding of tumor heterogeneity in lung SCC and connect normal epithelial differentiation programs to clinically meaningful phenomena such as platinum-based chemotherapy resistance.
Publication and authorship details reported in the source: the comment titled "A Barrier Betrayed: Hillock in Lung Squamous Cell Carcinoma" was authored by Xinyuan Tong and Hongbin Ji and published in Cancer Research (2026 Sep 15;86(18):4455-4456) with PMID 42740576 and DOI 10.1158/0008-5472.CAN-26-2945. The comment draws on and refers readers to the related original research article by Izzo et al. (Cancer Res. 2026;86:4472–4496) for experimental detail.
Limitations and source scope
This commentary summarizes and interprets the Izzo et al. findings as presented in the Cancer Research comment. Detailed experimental methods, quantitative data, and specific candidate therapeutic targets enriched in the KRT13+ state are reported in the original Izzo et al. article and are not reproduced in full in the comment. Where the comment references associations (for example, enrichment of therapeutic targets and chemotherapy resistance), the underlying experimental evidence and metrics are found in the related research article rather than in the brief commentary itself.